PAVmed Inc. (PAVM): Price and Financial Metrics
PAVM Price/Volume Stats
Current price | $0.40 | 52-week high | $2.34 |
Prev. close | $0.45 | 52-week low | $0.35 |
Day low | $0.40 | Volume | 571,800 |
Day high | $0.46 | Avg. volume | 482,061 |
50-day MA | $0.44 | Dividend yield | N/A |
200-day MA | $0.71 | Market Cap | 41.51M |
PAVM Stock Price Chart Interactive Chart >
PAVM POWR Grades
- PAVM scores best on the Growth dimension, with a Growth rank ahead of 79.37% of US stocks.
- The strongest trend for PAVM is in Momentum, which has been heading up over the past 173 days.
- PAVM ranks lowest in Quality; there it ranks in the 1st percentile.
PAVM Stock Summary
- PAVM's price/sales ratio is 62.65; that's higher than the P/S ratio of 96.86% of US stocks.
- PAVM's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 0.06% of US stocks.
- With a year-over-year growth in debt of 1,560.52%, PAVMED INC's debt growth rate surpasses 98.96% of about US stocks.
- Stocks that are quantitatively similar to PAVM, based on their financial statements, market capitalization, and price volatility, are OPFI, CURO, BOWL, MTD, and AON.
- Visit PAVM's SEC page to see the company's official filings. To visit the company's web site, go to www.pavmed.com.
PAVM Valuation Summary
- In comparison to the median Healthcare stock, PAVM's EV/EBIT ratio is 104.17% lower, now standing at -0.5.
- Over the past 83 months, PAVM's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for PAVM.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
PAVM | 2023-05-23 | 67.8 | -1.9 | -0.5 | -0.5 |
PAVM | 2023-05-22 | 70.8 | -2.0 | -0.5 | -0.5 |
PAVM | 2023-05-19 | 73.8 | -2.1 | -0.5 | -0.5 |
PAVM | 2023-05-18 | 74.1 | -2.1 | -0.5 | -0.5 |
PAVM | 2023-05-17 | 75.9 | -2.2 | -0.5 | -0.5 |
PAVM | 2023-05-16 | 85.6 | -2.5 | -0.6 | -0.6 |
PAVM Growth Metrics
- Its year over year cash and equivalents growth rate is now at 33.35%.
- Its 3 year net cashflow from operations growth rate is now at -317.74%.
- Its year over year net income to common stockholders growth rate is now at -96.67%.

The table below shows PAVM's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 0.565 | -70.939 | -86.017 |
2022-06-30 | 0.689 | -59.616 | -72.114 |
2022-03-31 | 0.689 | -43.686 | -58.064 |
2021-12-31 | 0.5 | -40.591 | -50.63 |
2021-09-30 | 0.2 | -30.542 | -42.157 |
2021-06-30 | 0 | -28.364 | -35.42 |
PAVM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PAVM has a Quality Grade of D, ranking ahead of 12.56% of graded US stocks.
- PAVM's asset turnover comes in at 0 -- ranking 171st of 186 Medical Equipment stocks.
- BBLG, SNN, and EYE are the stocks whose asset turnover ratios are most correlated with PAVM.
The table below shows PAVM's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0 | NA | 21.356 |
2021-03-31 | 0 | NA | 13.527 |
2020-12-31 | 0 | NA | 10.749 |
2020-09-30 | 0 | NA | 9.995 |
2020-06-30 | 0 | NA | 9.541 |
2020-03-31 | 0 | NA | 9.891 |
PAVM Price Target
For more insight on analysts targets of PAVM, see our PAVM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $5.08 | Average Broker Recommendation | 1.5 (Moderate Buy) |
PAVmed Inc. (PAVM) Company Bio
PAVmed Inc. operates as a medical device company in the United States. Its product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.
Latest PAVM News From Around the Web
Below are the latest news stories about PAVMED INC that investors may wish to consider to help them evaluate PAVM as an investment opportunity.
3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024These biotech stocks with high return potential are poised to provide quick returns for investors who invest over the next year. |
PAVmed Inc. (NASDAQ:PAVM) Q1 2023 Earnings Call TranscriptPAVmed Inc. (NASDAQ:PAVM) Q1 2023 Earnings Call Transcript May 17, 2023 PAVmed Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.21. Operator: Welcome to the PAVmed business update and first quarter 2023 financial results conference call. At this time, all participants are in a listen-only mode. Later we will conduct a question and […] |
Q1 2023 PAVmed Inc Earnings CallQ1 2023 PAVmed Inc Earnings Call |
PAVmed Provides Business Update and First Quarter Financial ResultsPAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the Company for the three months ended March 31, 2023. |
Lucid Diagnostics Provides Business Update and First Quarter Financial ResultsLucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today provided a business update for the Company and presented financial results for the three months ended March 31, 2023. |
PAVM Price Returns
1-mo | -14.68% |
3-mo | -18.37% |
6-mo | -42.49% |
1-year | -58.15% |
3-year | -79.80% |
5-year | -59.80% |
YTD | -16.67% |
2022 | -80.49% |
2021 | 16.04% |
2020 | 76.67% |
2019 | 24.74% |
2018 | -57.90% |
Loading social stream, please wait...